This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.
Conditions
- Type 2 Diabetes
Intervention
- Cagrilintide
- Semaglutide
- Tirzepatide
Principal Investigator
- Lee, Scott
Sponsor
- Novo Nordisk
*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/18/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.
Request Information
Complete the form below to contact the study team and receive more information about this trial.